Premium
Continuing medical education
Author(s) -
Esther Kristiningrum
Publication year - 2007
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.21754
Subject(s) - continuing education , citation , continuing medical education , library science , medicine , medical education , psychology , computer science
Osteoporosis is a systemic skeletal disease characterized by low bone mass and damage to bone microarchitecture with the consequence of more fragile and more easily fractured bone. Worldwide, 1 in 3 women and 1 in 5 men over age 50 will experience osteoporotic fractures. The goal of pharmacological therapy is to reduce the risk of fractures. Medications to treat osteoporosis are categorized as antiresorptive agents (i.e., bisphosphonates, estrogen, calcitonin, and denosumab) or anabolic agents (i.e., raloxifene and teriparatide). The first-line treatment for most postmenopause osteoporosis patients includes alendronate, risedronate, zoledronic acid, and denosumab. Esther kristiningrum. Pharmacotherapy of Osteoporosis.